NCT04857892View on ClinicalTrials.gov

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

September 10, 2021

Study Completion Date

September 10, 2021

Conditions
HIV Infections
Interventions
DRUG

GSK3640254

GSK3640254 will be administered via oral route.

DRUG

DTG

DTG will be administered via oral route.

DRUG

GSK3640254/DTG

GSK3640254/DTG will be administered via oral route.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY